2014
Fractional Flow Reserve-Guided PCI for Stable Coronary Artery Disease
DE BRUYNE, Bernard; William F. FEARON; Nico H.J. PIJLS; Emanuele BARBATO; Pim TONINO et al.Základní údaje
Originální název
Fractional Flow Reserve-Guided PCI for Stable Coronary Artery Disease
Autoři
DE BRUYNE, Bernard; William F. FEARON; Nico H.J. PIJLS; Emanuele BARBATO; Pim TONINO; Zsolt PIROTH; Nicola JAGIC; Sven MOBIUS-WINCKLER; Gilles RIOUFOL; Nils WITT; Petr KALA; Philip MACCARTHY; Thomas ENGSTRÖM; Keith OLDROYD; Kreton MAVROMATIS; Ganesh MANOHARAN; Peter VERLEE; Ole FROBERT; Nick CURZEN; jane B. JOHNSON; Andreas LIMACHER; Eveline NÜESCH a Peter JÜNI
Vydání
New England Journal of Medicine, Waltham, Massachussetts Medical Society, 2014, 0028-4793
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 55.873
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/14:00078384
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
angiotensin receptor antagonist; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase inhibitor
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 1. 2015 17:46, Soňa Böhmová
Anotace
V originále
BACKGROUND We hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention (PCI) performed on the basis of the fractional flow reserve (FFR) would be superior to medical therapy. METHODS In 1220 patients with stable coronary artery disease, we assessed the FFR in all stenoses that were visible on angiography. Patients who had at least one stenosis with an FFR of 0.80 or less were randomly assigned to undergo FFR-guided PCI plus medical therapy or to receive medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy alone and were included in a registry. The primary end point was a composite of death from any cause, nonfatal myocardial infarction, or urgent revascularization within 2 years. RESULTS The rate of the primary end point was significantly lower in the PCI group than in the medical-therapy group (8.1% vs. 19.5%; hazard ratio, 0.39; 95% confidence interval [CI], 0.26 to 0.57; P<0.001). This reduction was driven by a lower rate of urgent revascularization in the PCI group (4.0% vs. 16.3%; hazard ratio, 0.23; 95% CI, 0.14 to 0.38; P<0.001), with no significant between-group differences in the rates of death and myocardial infarction. Urgent revascularizations that were triggered by myocardial infarction or ischemic changes on electrocardiography were less frequent in the PCI group (3.4% vs. 7.0%, P = 0.01). In a landmark analysis, the rate of death or myocardial infarction from 8 days to 2 years was lower in the PCI group than in the medical-therapy group (4.6% vs. 8.0%, P = 0.04). Among registry patients, the rate of the primary end point was 9.0% at 2 years. CONCLUSIONS In patients with stable coronary artery disease, FFR-guided PCI, as compared with medical therapy alone, improved the outcome. Patients without ischemia had a favorable outcome with medical therapy alone.